Neoplasms
The Haemato‑Onkologie Hamburg – Prof. Laack und Partner concentrates on cancer research, targeting TROP2‑positive advanced or metastatic non‑squamous non‑small cell lung cancer. Ongoing studies evaluate the safety and efficacy of the antibody‑drug conjugate datopotamab deruxtecan versus standard chemotherapy, with the goal of improving patient outcomes such as progression‑free and overall survival.
- Evaluation of a novel antibody‑drug conjugate for lung cancer
- Direct comparison with standard docetaxel therapy
- Measurement of progression‑free survival and overall survival benefits
With two investigators working at the Hamburg location, the site demonstrates a focused commitment to expanding therapeutic options for patients without actionable genomic alterations.
